Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1994 Jun;29(3):299-304.
doi: 10.1007/BF02358369.

Interferon retreatment of nonresponders with HCV-RNA-positive chronic hepatitis C

Affiliations
Clinical Trial

Interferon retreatment of nonresponders with HCV-RNA-positive chronic hepatitis C

Y Arase et al. J Gastroenterol. 1994 Jun.

Abstract

Interferon has been shown to be an effective treatment for some patients with chronic hepatitis C. In this study, the value of retreatment of nonresponders to interferon was investigated. Thirty-eight patients with hepatitis C virus (HCV)-RNA-positive chronic hepatitis C who had been treated with beta-interferon but still showed an alanine aminotransferase (ALT) level > 50 KU upon completion of therapy were retreated with alpha-interferon. Eight patients (21.1%) had normalization of ALT levels for at least 6 months after the completion of retreatment. The factors related to normalization of ALT levels after interferon retreatment were studied. Of 16 patients with transient HCV-RNA negativity 1 month after the initial interferon therapy, 7 (43.8%) had a complete response, with normalization of ALT levels and undetectable HCV-RNA, more than 6 months after interferon retreatment. On the other hand, of the 22 patients with HCV-RNA activity 1 month after the initial interferon therapy, only 1 (4.5%) had a complete response. Multivariate analysis, using a multiple logistic model, indicated that a complete response to readministration of interferon was most strongly correlated to transient negative conversion for HCV-RNA after the initial course of treatment.

PubMed Disclaimer

References

    1. Lancet. 1987 Mar 7;1(8532):539-41 - PubMed
    1. Gastroenterol Jpn. 1992 Oct;27(5):646-51 - PubMed
    1. N Engl J Med. 1989 Nov 30;321(22):1506-10 - PubMed
    1. Nucleic Acids Res. 1989 Dec 25;17(24):10367-72 - PubMed
    1. Dig Dis Sci. 1989 Mar;34(3):330-7 - PubMed

LinkOut - more resources